Skip to main content
Joanne Weidhaas, MD, Radiation Oncology, Los Angeles, CA

Joanne B Weidhaas MD PHD, MSM


Professor, David Geffen School of Medicine at UCLA

Join to View Full Profile
  • 200 Medical Plaza, Suite B265Los Angeles, CA 90095

  • Phone+1 310-825-9775

  • Fax+1 310-825-9775

Dr. Weidhaas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Stanford Graduate School of Business
    Stanford Graduate School of BusinessMS, Management, 2012 - 2013
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2000 - 2004
  • Steward Carney Hospital
    Steward Carney HospitalInternship, Internal Medicine, 1999 - 2000
  • Tufts Sackler School
    Tufts Sackler SchoolPhD, Molecular Biology and Microbiology, 1991 - 1999
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1999
  • Yale University
    Yale UniversityBS, Biology, 1986 - 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2015 - 2027
  • CT State Medical License
    CT State Medical License 2004 - 2017
  • NY State Medical License
    NY State Medical License 2000 - 2006
  • Radiation Oncology
    American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Yale Cancer Center Award, “Most Influential Paper in the Field" 2009
  • Michael Fry Research Award 2009
  • Recognition of Clinical Excellence Award Yale School of Medicine, 2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab M...  
    Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S, Clin Cancer Res, 9/1/2014
  • A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma  
    Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 7/1/2014
  • Radiation therapy oncology group gynecologic oncology working group: comprehensive results  
    Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr, Int J Gynecol Cancer, 6/1/2014
  • Join now to see all

Lectures

  • The KRAS-variant in Head and Neck Cancer as a Predictive Biomarker, results of RTOG 0522 
    6/1/2014
  • MicroRNAs in cancer risk, biology and treatment 
    4/1/2014
  • Yale Cancer Center Evening Oncology Series: Breast Cancer 
    Yale CME, New Haven, Connecticut - 1/17/2012
  • Join now to see all

Press Mentions

  • MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer
    MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate CancerApril 7th, 2025
  • New Test Identifies Prostate Cancer Patients at Risk for Long-Term Radiation Therapy Side Effects
    New Test Identifies Prostate Cancer Patients at Risk for Long-Term Radiation Therapy Side EffectsApril 7th, 2025
  • Test Predicts Which Patients with Prostate Cancer Most Likely to Develop Long-Term Side Effects from Radiation Therapy
    Test Predicts Which Patients with Prostate Cancer Most Likely to Develop Long-Term Side Effects from Radiation TherapyApril 7th, 2025
  • Join now to see all

Grant Support

  • Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionUNIVERSITY OF CALIFORNIA LOS ANGELES2019–2025
  • Let-7 Micrornas In Lung Cancer: Altering Growth And RadioresistanceNational Cancer Institute2009–2012
  • Defining The Genetic Basis Of The Radioresponse Using A C. Elegans Tissue ModelNational Cancer Institute2007–2011

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: